1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Cerebral palsy

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide

Evidence summary [ES5] Published: 14 February 2017

  • Key points
  • Introduction and current guidance
  • Product overview
  • Evidence review
  • Estimated impact for the NHS
  • Information for the public about medicines
  • Relevance to other NICE programmes
  • References
  • Evidence tables
  • Results tables
  • Excluded studies
  • Terms used in this evidence summary
  • Search strategy
  • Development of this evidence summary
Download (PDF)

Advice

  • Next

References

References

Mier RJ, Bachrach SJ, Lakin RC et al. (2000) Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Archives of Pediatrics and Adolescent Medicine 154: 1214–8

Zeller RS, Lee HM, Cavanaugh PF et al. (2012a) Randomized phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Therapeutics and Clinical Risk Management 8: 15–23

Zeller RS, Davidson J, Lee HM et al. (2012b) Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions. Therapeutics and Clinical Risk Management 8: 25–32


  • Next